Precision-Panc Master Protocol: Personalising Treatment for Pancreatic Cancer
NCT ID: NCT04161417
Last Updated: 2024-02-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
2500 participants
INTERVENTIONAL
2017-11-28
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PRIMUS 001: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer
NCT04151277
PRIMUS002: Looking at 2 Neo-adjuvant Treatment Regimens for Resectable and Borderline Resectable Pancreatic Cancer
NCT04176952
Pancreatic Cancer Dietary Assessment Study
NCT03616431
Determining Individualized Cancer Therapy in Pancreatic Cancer
NCT05914987
A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer
NCT04229004
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Biopsy Material Required for Registration
The Precision-Panc Master Protocol aims to recruit, consent and screen patients with pancreatic cancer
Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling
Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling. This will enable patient enrolment into a currently available PRIMUS study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling
Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling. This will enable patient enrolment into a currently available PRIMUS study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Either:
* Presence of a hypodense pancreatic mass highly suspicious of primary pancreatic cancer with or without distant metastasis as assessed by a Pancreatic Multi-Disciplinary Team (MDT).
Or
o Histologically or cytologically confirmed pancreatic ductal adenocarcinoma and its variants.
* Patient is willing and able to undergo additional tumour biopsy (from the primary or a metastatic site) aimed at obtaining sufficient tissue for molecular profiling if this is required.
* Patient is deemed suitable to receive chemotherapy and/or radiotherapy, and/or surgery pending stage of disease at presentation.
* Patient is deemed potentially eligible for a currently open PRIMUS study
* Patient has signed informed consent for screening research tumour biopsy (Consent 1).
* Patient has signed informed consent for Precision-Panc Master Protocol molecular profiling (Consent 2).
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cancer Research UK
OTHER
NHS Greater Glasgow and Clyde
OTHER
Judith Dixon-Hughes
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Judith Dixon-Hughes
Project Manager
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Chang
Role: PRINCIPAL_INVESTIGATOR
University of Glasgow
Juan Valle
Role: PRINCIPAL_INVESTIGATOR
University of Manchester
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aberdeen Royal Infirmary
Aberdeen, , United Kingdom
Northern Ireland Cancer Centre
Belfast, , United Kingdom
Queen Elizabeth Hospital
Birmingham, , United Kingdom
Royal Bournemouth Hospital
Bournemouth, , United Kingdom
Bristol Oncology Centre
Bristol, , United Kingdom
Addenbrooke's Hospital
Cambridge, , United Kingdom
Castle Hill Hospital
Cottingham, , United Kingdom
Ninewells Hospital
Dundee, , United Kingdom
Western General
Edinburgh, , United Kingdom
Glasgow Royal Infirmary
Glasgow, , United Kingdom
Huddersfield Royal Infirmary
Huddersfield, , United Kingdom
Raigmore Hospital
Inverness, , United Kingdom
St James's Hospital
Leeds, , United Kingdom
Royal Liverpool Hospital
Liverpool, , United Kingdom
Guy's Hospital
London, , United Kingdom
Imperial College Healthcare Trust
London, , United Kingdom
King's College Hospital
London, , United Kingdom
Royal Free London Hospital
London, , United Kingdom
Royal Marsden Hospital
London, , United Kingdom
St Bart's Hospital
London, , United Kingdom
St George's Hospital
London, , United Kingdom
University College London Hospital
London, , United Kingdom
Manchester Royal Infirmary
Manchester, , United Kingdom
The Christie, Manchester
Manchester, , United Kingdom
Milton Keynes Hospital
Milton Keynes, , United Kingdom
Freeman Hospital
Newcastle, , United Kingdom
Nottingham Hospitals NHS Trust
Nottingham, , United Kingdom
Churchill Hospital
Oxford, , United Kingdom
Pool Hospital
Poole, , United Kingdom
Weston Park
Sheffield, , United Kingdom
University Hospital Southampton
Southampton, , United Kingdom
Morriston Hospital
Swansea, , United Kingdom
Royal Albert Edward Infirmary
Wigan, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Olga Demyanov
Role: primary
Laura McLennan
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Saha A, Wadsley J, Sirohi B, Goody R, Anthony A, Perumal K, Ulahanan D, Collinson F. Can Concurrent Chemoradiotherapy Add Meaningful Benefit in Addition to Induction Chemotherapy in the Management of Borderline Resectable and Locally Advanced Pancreatic Cancer?: A Systematic Review. Pancreas. 2023 Jan 1;52(1):e7-e20. doi: 10.1097/MPA.0000000000002215.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GN17on293
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.